Glomerulonephritis outcome

Conjeevaram, H.S., J.H. Hoofnagle, H.A. Anstin, Y. Park, M.W. Pried, and A.M. Di Bisceglie, Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology, 1995.109 540-46. 

Fujieda M, Hattori M, Kurayama H, Koitabashi Y. Members and Coworkers of the Japanese Society for Pediatric Nephrology. Clinical features and outcomes in children with antineutrophil cytoplasmic autoantibodypositive glomerulonephritis associated with propylthiouracil treatment. J Am Soc Nephrol 2002 13(2) 437 I5. 

Long-term outcomes in a series of seven children who developed myeloperoxidase-specific ANCA-positive necrotizing crescentic glomerulonephritis associated with propylthiouracil were studied in Japan (67). Three had nephritis alone and four had extrarenal vasculitis. All had taken glucocorticoids, some with additional drugs, and aU... 

In the kidney, clusterin is a component of immune deposits and its expression is increased after ischemia or obstruction. In gentamicin-treated rats, an increase in urinary clusterin protein may provide an early sign of nephrotoxicity [336]. In rats with unilatertral ureteral obstruction, clusterin mRNA and clusterin-beta have been detected in the kidney along with clusterin-alpha in the urine [337]. A central role for glomerular clusterin as a modulator of inflammation that potentially influences the chnical outcome in human membranous glomerulonephritis has been described [338]. 

Holdsworth SR, Kitching AR, Tipping PG Thl and Th2T helper cell subsets affect patternsofinjury and outcomes in glomerulonephritis. Kidney Int 1999 55 1198-216. 

Bazzi C, Petr ini C, Rizza V, Arrigo G, Napodano P, PapareUa M, et al. Urinary N-acetyl-p-D-glucosaminidase excretion as a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant 2002 17 1890-6. 

Hauer HA, Bajema IM, Van-Houwelingen HC, Ferrario F, Noel LH, Waldherr R, et al. Determinants of outcome in ANCA-associated glomerulonephritis a prospective cHnico-histopathological analysis of 96 patients. Kidney Int 2002 62 1732-42. 

Glomerulonephritis is a collection of glomerular diseases mediated by different immunologic pathogenic mechanisms, resulting in varied clinical presentation and therapeutic outcomes. 

Various new experimental agents, such as etanercept and alem-tuzumab, have also been used to treat glomerulonephritis. Sufficient experiences are not yet available to determine their role in therapy. However, as we acquire further understanding of the pathogenic processes, iimovative therapy can be developed to improve patient outcome. 

Glomerulonephritis is one of the most serious complications of systemic lupus erythematosus (SLE) and accounts for much of the morbidity and mortality of patients afflicted with the disease. The renal manifestations of lupus nephritis are variable and encompass a wide spectrum of histopathologic lesions. ° ° The underlying histopathology is associated with different prognoses and responses to therapy, which cannot be predicted solely based on clinical manifestations. A renal biopsy is therefore required to assess the severity of the disease and to predict the short-term and long-term outcomes associated with therapy. Drugs, such as hydralazine and procainamide, are known to precipitate a lupus syndrome however, they are unlikely to cause disease that affects the kidney. 

Extracapillary glomerulonephritis with renal vasculitis is also been reported as a rare complication of D-penidllamine therapy [117,126,156]. Necrosis of interlobular arteries with glomerular crescent [117] and necrotic and ocduded periglomerular arterioles [156] have been reported. Aggressive treatment with pulse steroid, anticoagulants, and antiplatelet agents may be beneficial. The two patients with renal vasculitis, whose outcome was known, died from bacterial infection within ten months after the onset of the disease [117,... 

Franssen CF, Stegeman CA, Oost-Kort WW, et al. Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis. J Am Soc Nephrol 1998 9(10) 1915-1923. 

Langford CA, Talar-WilUams C, SneUer MC. Use of methotrexate and glucocorticoids in the treatment of Wegener s granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000 43(8) 1836-1840. 

---